Core and Main Inc vs Revvity Inc — how do they compare? Core and Main Inc trades at $46.18 (market cap $8.73B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.24% dividend while Core and Main Inc pays none. Which is the better fit depends on your goals.
| CNM | RVTY | |
|---|---|---|
Market Cap | $8.73B | $12.91B |
Sector | Technology | Technology |
52-Week High | $66.98 | $117.75 |
52-Week Low | $42.37 | $82.26 |
Enterprise Value | $11.02B | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Core & Main (CNM) trades at $46.06, down 0.52% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.57 exceeding expectations. Financials show solid profitability with a 5.87% net income margin and 23.73% ROE, though debt levels remain elevated. Recent news includes institutional position adjustments and a $750 million senior notes offering priced in June 2026.
Outlook is cautiously optimistic with analyst consensus favoring Buy ratings (57%). Key opportunities include margin expansion and municipal strength, while risks involve high debt, competitive pressures, and reliance on infrastructure spending. The stock's valuation at a P/E of 19.76 appears reasonable given growth prospects, but investors should monitor execution against FY26 revenue guidance of $7.8–7.9 billion.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Trailing returns across standard periods
Latest headlines on both assets
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →